Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00783211
First received: October 30, 2008
Last updated: April 25, 2014
Last verified: April 2014
  Purpose

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.


Condition Intervention Phase
Seasonal Allergic Rhinitis
Drug: desloratadine
Drug: fexofenadine
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Compare the efficacy of the study treatments with respect to the change from Baseline in the mean AM self-rated instantaneous total symptom score (TSS) (not including nasal congestion) averaged over the 15 days of treatment [ Time Frame: 15 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in the mean AM/PM self-rated 12-hour reflective TSS (not including nasal congestion) averaged over the 15 days of treatment. [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • Change from Baseline in the mean AM self-rated instantaneous individual symptom scores, including nasal congestion, averaged over the 15 days of treatment. [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • Change from Baseline in the mean AM/PM self-rated 12-hour reflective individual symptom scores, including nasal congestion, averaged over the 15 days of treatment. [ Time Frame: 15 days ] [ Designated as safety issue: No ]
  • Joint physician-patient evaluation of response to therapy. [ Time Frame: Day 8 and Day 15 ] [ Designated as safety issue: No ]

Enrollment: 722
Study Start Date: August 2004
Study Completion Date: October 2004
Primary Completion Date: October 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
desloratadine
Drug: desloratadine
desloratadine, 5 mg oral tablets, once daily for 15 days
Other Name: SCH 34117; Clarinex
Active Comparator: 2
fexofenadine
Drug: fexofenadine
fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
Other Name: Allegra
Placebo Comparator: 3
placebo
Drug: placebo
placebo, once daily for 15 days

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • have demonstrated their willingness to participate in the study and comply with its procedures, including adherence to dosing and visit schedules by signing a written informed consent (the parent/guardian of a subject under 18 years of age also had to sign the informed consent form);
  • have been 12 years of age or older, of either sex and any race;
  • have had at least a 2-year history (self-reported history was acceptable) of seasonal allergic rhinitis occurring during the same season(s) as the current study;
  • have been skin test positive (skin prick test with a wheal diameter at least 3 mm larger than the diluent control or intradermal testing with a wheal diameter at least 7 mm larger than the diluent control) at Screening, or within 12 months prior to the Screening Visit, to an appropriate seasonal allergen, which could include seasonal molds, prevalent in the geographical area of the study site during the study period;
  • if female and of childbearing potential (including women who were less than 1 year postmenopausal and women who became sexually active during the study), have been using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation);
  • if female and of childbearing potential, have had a negative urine pregnancy test at Baseline;
  • have been free of any clinically significant disease (other than SAR) that would interfere with study evaluations;
  • have understood and been able to adhere to the dosing and visit schedules, and agreed to record symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary;
  • have met the following at the Screening Visit: total symptom score (TSS) of 6 or greater (not including congestion), with 2 or more symptoms rated as moderate (2) or severe (3) and no symptom rated as very severe (4) during the 12 hours prior to this visit;
  • have met the following on the morning of the Baseline Visit: symptom severity score 7 AM instantaneous TSS of 6 or more (not including congestion), with 2 or more symptoms rated as moderate (2) or severe (3), and no symptom rated as very severe (4).

Exclusion Criteria:

  • if female, were pregnant, intended to become pregnant during the study, or were nursing;
  • had not observed the designated washout periods for any of the prohibited medications;
  • had current evidence of clinically significant hematopoietic, cardiovascular, hepatic, immunologic, renal, neurologic, psychiatric, autoimmune disease, or other disease that precluded the subject's participation in the study; particular attention was to be given to conditions that would interfere with the absorption, distribution, metabolism or excretion of the study drug, or with the subject's ability to complete the diary cards;
  • had any clinically significant deviation from normal in the physical examination that, in the investigator's judgment, may have interfered with the study evaluation or affected subject safety;
  • were in a situation or condition that, in the opinion of the investigator, may have interfered with optimal participation in the study;
  • were participating in any other clinical study(ies);
  • were part of the investigational study staff or a family member of the staff personnel directly involved with this study;
  • had asthma, with the exception of mild intermittent asthma, ie, controlled with the use of short acting, beta2-agonist adrenoreceptor rescue medication;
  • had a current or past history of frequent (2 or more episodes per year for the past 2 years), clinically significant sinusitis or chronic purulent postnasal drip;
  • had rhinitis medicamentosa;
  • had a history of intranasal drug abuse;
  • had a history of hypersensitivity to the study drugs or their excipients, or to Claritin;
  • had an upper respiratory tract or sinus infection that required antibiotic therapy with the last dose within 14 days prior to Screening, or had a viral upper respiratory infection within 7 days prior to Screening, or had persistent symptoms at the time of the Screening Visit;
  • had nasal structural abnormalities, including nasal polyps easily visible on physical examination and marked septum deviation that significantly interfered with nasal airflow;
  • in the opinion of the investigator, were dependent upon nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids;
  • if on immunotherapy (desensitization therapy) should not have had a change in dose during the study, and should have remained on the same dose throughout the trial; were not to have received desensitization treatment within 24 hours prior to a visit;
  • had been previously randomized into the study at any study site;
  • ability to provide informed consent was compromised;
  • had a history of non-compliance with medications or treatment protocols;
  • had a history of difficulty swallowing pills or had known upper gastrointestinal narrowing or abnormal esophageal peristalsis;
  • was a night-shift worker or did not have a standard asleep at night / awake during the day cycle;
  • planned to travel outside of the study area during the time of their participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00783211     History of Changes
Other Study ID Numbers: P04053
Study First Received: October 30, 2008
Last Updated: April 25, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Seasonal
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Desloratadine
Fexofenadine
Terfenadine
Anti-Allergic Agents
Cholinergic Agents
Cholinergic Antagonists
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014